MeMed is a series c plus startup based in Israel. 1 investor tracked on Brouky Intelligence. Data sourced from Brouky Intelligence.
About
MeMed develops and commercializes diagnostic solutions that decode the body's immune response to enable physicians to make informed decisions.
Stage
series-c-plus
Investors
1
See full investor history, risk signals & comparable companies
Brouky tracks 15,000+ startups with funding rounds, risk analysis, and AI-powered investor matching.
Subscribe to Brouky